SUO 2018: The Microbiome and Prostate Cancer Risk
Phoenix, Arizona (UroToday.com) Dr. Michael A. Liss presented the risk of prostate cancer and the microbiome. There has been some evidence that various gut microbiota promotes antitumor immunity and facilitates anti-PDL1 efficacy1. On the other hand, there is some evidence that other microbiota can enhance the risk for prostate cancer in mice models.
SUO 2018: Variations in the Microbiome in Men Receiving ADT
Phoenix, Arizona (UroToday.com) Dr. Karen Sfanos presented the variations in the microbiome in men who receive androgen deprivation therapy (ADT). The microbiome is regarded as the forgotten organ. Our microbes are crucial to our function and can do some things that we cannot do. These include:
SUO 2018: ProVent: A Phase 3 Study of Sipuleucel-T Therapy in Subjects with Localized Prostate Cancer Followed by Active Surveillance
Phoenix, Arizona (UroToday.com) Differentiating between low grade prostate cancer that will remain indolent to one that will progress is quite challenging. The goal of active surveillance is to reduce overtreatment while retaining the option of treating patients who develop high-risk features. Radical definitive treatment with either radical prostatectomy or radiation therapy although effective, is associated with significant short and long-term side effects. These include sexual dysfunction, urinary incontinence and bowel issues.
SUO 2018: Obesity and Metastatic Castration Resistant Prostate Cancer: Results From The Control Arms of ASCENT2, MAINSAIL and VENICE Trials
Phoenix, Arizona (UroToday.com) Although there is a known correlation between obesity and prostate cancer, the role of body mass index (BMI) in metastatic castration-resistant prostate cancer (mCRPC) is unclear. Moreover, the correlation between BMI and survival outcomes in prostate cancer is also unclear.
SUO 2018: Pooled Results From Two Prospective Validation Studies of the EPI Test Demonstrates Consistent Performance to Predict High-grade Prostate Cancer at Initial Biopsy
Phoenix, Arizona (UroToday.com) As our knowledge of prostate cancer (PCa) continues to grow, we have increasingly come to accept the fact that there is a subset of PCa that has little long-term clinical implications and can be watched – clinically insignificant prostate cancer, often Gleason 6 PCa (Gleason Grade Group 1).
SUO 2018: Immune Response in Patients With Metastatic Renal Cell Carcinoma Treated With AdGMCA9
Phoenix, Arizona (UroToday.com) The management of mRCC is undergoing significant changes. The recent introduction of immunotherapies is changing a field that has long been dominated by targeted therapies – and some have demonstrated promising durable responses rarely seen before. The era of immunotherapies (PD-1, PD-L1 and CTLA-4 targeted treatments) is upon us. However, novel targeted therapies, including cabozantinib, have demonstrated improved outcomes compared to the prior standards.